BiomX Inc
PHGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.01M
Close$
$0.00
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.01 Million |
|---|---|
| Enterprise Value | $839,894.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.19 |
| Beta | 1.03 |
| Outstanding Shares | 2,603,807 |
Return
| Return on Equity | -8181.61% |
|---|---|
| Return on Assets | 2217.16% |
| Return on Invested Capital | 3231.22% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | -0.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.03 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.45%▲ 0.02% |
|---|---|
| Total Invested | $1.19M▲ 109.81% |
| Investors Holding | 13▲ 3.00% |
ESG Score
No data
About BiomX Inc
101 employeesBiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic dis...